Latest Cancer treatments Stories
Lee Rannals for redOrbit.com – Your Universe Online According to research led by St. Jude Children's Research Hospital, there is a connection between higher rates of relapse in pediatric cancer patients and drug shortages. A national drug shortage was linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin's lymphoma, according to the national study. Survival from the condition went from 88 to 75 percent in two years after the drug...
National study connects higher rates of relapse in pediatric cancer patients to drug shortage, offering first example of patients hurt by shortages and renewing calls to protect patient access to lifesaving treatments MEMPHIS, Tenn., Dec. 26, 2012 /PRNewswire-USNewswire/ -- A national drug shortage has been linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma enrolled in a national clinical trial, according to research led by St. Jude...
redOrbit Staff & Wire Reports - Your Universe Online While it has become an iconic symbol of holiday romance, mistletoe may contain a substance that could help in the treatment of colon cancer, researchers from the University of Adelaide in Australia discovered in a recent study. The research, which was featured in a Huffington Post article published Friday, discovered the plant's extract was actually more effective in eliminating colon cancer cells than chemotherapy. Furthermore,...
AMES, Iowa, Dec. 13, 2012 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the results of a Phase 1 dose escalation study with its proprietary HyperAcute Prostate Cancer Immunotherapy were published in the Journal of Immunotherapy. The article, entitled "Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted From Prostate Tumor-associated Autoantigens," is featured in the current edition of...
WINSTON-SALEM, N.C., Dec. 11, 2012 /PRNewswire-USNewswire/ -- When Teresa Thorn started getting nausea last February, she thought it was an ulcer, something she'd had years earlier. As the days went on, though, the nausea remained and Thorn's color started changing, something her co-workers noticed. Finally one Sunday, she and her mother, Naomi Ivester, went to the Emergency Department at Wake Forest Baptist Medical Center, where a battery of tests began. Her longtime physician at...
A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care. “We’re in a new paradigm in which we realize this top cause of cancer deaths is actually a number of related diseases, each potentially with its own cause and cure,” Bunn says. The review describes the shift from blanketing lung...
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston. The trial leaders will present the results of the Dana-Farber Cancer Institute ALL Consortium study, which involved nearly 500 patients under age 18 with B-precursor acute...
Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a large number of women with early stage HER2-positive breast cancer. But trastuzumab does not stop tumors from returning in about 25 percent of patients — and oncologists haven't been able to identify these women before treatment. This situation may soon change, according to a Mayo Clinic study being presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. A team of U.S....
REDWOOD CITY, Calif., Dec. 10, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the results from six studies of the Oncotype® DX breast cancer test presented at the 34(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) reinforcing the impact of the test on facilitating better informed treatment decisions in patients with node-negative and node-positive invasive early-stage breast cancer. Additionally, two studies demonstrated the test's cost...
University of Pennsylvania Researchers Report on Results of Trial in 12 Patients, Including Two Children ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania. Penn Medicine researchers will present the...
